 "Nasal Covid spray")
Glenmark Pharmaceuticals plans to test its upcoming nitric oxide nasal spray (NONS) that it has licensed from a Canadian Biotech firm as a preventive measure for Covid-19.
The firm, which has tasted success with its oral antiviral drug favipiravir, is now betting on the NONS to drive revenues from its Covid-19 portfolio.
In the first quarter, Covid-19 revenues were a tad less than 10 per cent of Glenmark’s turnover. Favipiravir alone sold for around Rs 350 crore, boosting its India business by 57 per cent year-on-year (YoY). What’s more? Fabiflu (Glenmark’s brand of favipiravir) enjoys margins of 35
The firm, which has tasted success with its oral antiviral drug favipiravir, is now betting on the NONS to drive revenues from its Covid-19 portfolio.
In the first quarter, Covid-19 revenues were a tad less than 10 per cent of Glenmark’s turnover. Favipiravir alone sold for around Rs 350 crore, boosting its India business by 57 per cent year-on-year (YoY). What’s more? Fabiflu (Glenmark’s brand of favipiravir) enjoys margins of 35
